公开(公告)号：US20200215063A1

公开(公告)日：2020-07-09

申请号：US16820794

申请日：2020-03-17

Applicant: Intelgenx Corp.

Inventor： Horst G. Zerbe ,  Nadine Paiement ,  Angela Angusti ,  Cormac Long ,  Rodolphe Obeid ,  Laetitia Rodes ,  Billal Tir

IPC: A61K31/4985 ,  A61K9/00 ,  A61K9/70

Abstract: Oral film dosage forms that provide improved solubilization and stabilization of an active ingredient in particle form include at least one primary crystallization inhibitor in an amount that inhibits growth and/or agglomeration of the active ingredient, a polyoxyethylated fatty acid glycerides in an amount that further enhances inhibition of crystallization, growth and agglomeration of the particles of the pharmaceutically active ingredient; and at least one plasticizer present in an amount that is effective to increase flexibility and elasticity of the film dosage form.

公开(公告)号：US20180110724A1

公开(公告)日：2018-04-26

申请号：US15848819

申请日：2017-12-20

Applicant: Intelgenx Corp.

Inventor： Horst G. Zerbe ,  Nadine Paiement ,  Cormac Long ,  Rodolphe Obeid

IPC: A61K9/00 ,  A61K9/14 ,  A61K9/70 ,  A61K31/4985 ,  A61K31/4709 ,  A61K31/58 ,  A61K31/19 ,  A61K31/40 ,  A61K31/34 ,  A61K31/496 ,  A61K31/439 ,  A61K31/553 ,  A61K31/353 ,  A61K47/14

CPC classification number: A61K9/006 ,  A61K9/14 ,  A61K9/145 ,  A61K9/1635 ,  A61K9/7007 ,  A61K31/19 ,  A61K31/34 ,  A61K31/353 ,  A61K31/40 ,  A61K31/439 ,  A61K31/4709 ,  A61K31/496 ,  A61K31/4985 ,  A61K31/553 ,  A61K31/58 ,  A61K47/14

Abstract: Oral film dosage forms that provide improved solubilization and stabilization of an active ingredient in particle form include at least one primary crystallization inhibitor in an amount that inhibits growth and/or agglomeration of the active ingredient, a polyoxyethylated fatty acid glycerides in an amount that further enhances inhibition of crystallization, growth and agglomeration of the particles of the pharmaceutically active ingredient; and at least one plasticizer present in an amount that is effective to increase flexibility and elasticity of the film dosage form.

公开(公告)号：US20170157119A1

公开(公告)日：2017-06-08

申请号：US15426149

申请日：2017-02-07

Applicant: Intelgenx Corp.

Inventor： Horst G. Zerbe ,  Nadine Paiement ,  Angela Angusti ,  Cormac Long ,  Rodolphe Obeid

IPC: A61K31/4985 ,  A61K47/14 ,  A61K47/44 ,  A61K47/12 ,  A61K47/10 ,  A61K9/00 ,  A61K47/26

CPC classification number: A61K31/4985 ,  A61K9/006 ,  A61K9/7007

Abstract: Oral film dosage forms that provide improved solubilization and stabilization of an active ingredient in particle form include at least one primary crystallization inhibitor in an amount that inhibits growth and/or agglomeration of the active ingredient, a polyoxyethylated fatty acid glycerides in an amount that further enhances inhibition of crystallization, growth and agglomeration of the particles of the pharmaceutically active ingredient; and at least one plasticizer present in an amount that is effective to increase flexibility and elasticity of the film dosage form.

公开(公告)号：US20180078549A1

公开(公告)日：2018-03-22

申请号：US15822734

申请日：2017-11-27

Applicant: Intelgenx Corp.

Inventor： Horst G. Zerbe ,  Nadine Paiement ,  Angela Angusti ,  Cormac Long

IPC: A61K31/4985 ,  A61K9/00

CPC classification number: A61K31/4985 ,  A61K9/006

Abstract: Improved pharmaceutical solid oral dosage forms for the buccal and/or sublingual delivery of Tadalafil. The improved delivery systems for solubilizing and stabilizing pharmaceutically active ingredients exhibit enhanced methods of preparation by the use improved solubilization systems which can maintain the Tadalafil in a buccal and/or sublingual oral dosage form or a polymeric film matrix that provides improved bioavailability and/or absorption of Tadalafil.